nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.06.2008

Mineral metabolism and bone abnormalities in children with chronic renal failure

verfasst von: Cheryl P. Sanchez

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Abnormalities in mineral metabolism and changes in skeletal histology may contribute to growth impairment in children with chronic renal failure. Hyperphosphatemia, hypocalcemia, metabolic acidosis, alterations in vitamin D and IGF synthesis and parathyroid gland dysfunction play significant roles in the development of secondary hyperparathyroidism and subsequently, bone disease in renal failure. The recent KDIGO conference has made recommendations to consider this as a systemic disorder (chronic kidney disease-mineral bone disorder) and to standardize bone histomorphometry to include bone turnover, mineralization and volume (TMV). The use of DXA to assess bone mass is controversial in children with chronic renal failure. Questions arise regarding the accuracy of bone measurements and difficulty in data interpretation especially in children with renal failure who are not only growth retarded but often have pubertal delay and osteosclerosis. The validity and feasibility of new modalities of skeletal imaging which can detect changes in both trabecular and cortical bone are currently being investigated in children. The management of mineral abnormalities and bone disease in chronic renal failure is multifactorial. To manage hyperphosphatemia, dietary phosphate restriction accompanied by intake of calcium-free and metal-free phosphate binding agents are widely utilized. Vitamin D analogs remain the primary therapy for secondary hyperparathyroidism, although the use of the less hypercalcemic agents is preferred due to concerns of calciphylaxis and vascular calcification. Future clinical studies are needed to evaluate the long-term effects of calcimimetic agents and bisphosphonate therapy in children with chronic renal failure.

Seikaly M, Salhab N, Gipson D, Yiu V, Stablein D. stature in children with chronic kidney disease: Analysis of NAPRCTS database. Pediatr Nephrol. 2006;21(6):793–9.PubMedCrossRef

Lewis M, Shaw J, Reid C, Evans J, Webb N, Verrier-Jones K. Growth in children with established renal failure a registry analysis. Nephrol Dial Transplant. 2007;22(suppl 7):176–80.

Wong C, Gipson D, Gillen D, Emerson S, Koepsell T, Sherrard D, et al. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis. 2000;36(4):811–9.PubMedCrossRef

Furth SL, Hwang W, Yang C, Neu A, Fivush B, Powe N. Growth Failure, Risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol. 2002;17(6):450–5.PubMedCrossRef

Rosenkranz J, Bonzel K-E, Bulla M, Michalk D, Offner G, Reichwald-Klugger E, et al. Psychosocial adaptation of children and adolescents with chronic renal failure. Pediatr Nephrol. 1992;6:459–63.PubMedCrossRef

Moe S, Cunningham J, Goodman WG, Martin K, Olgaard K, Ott S, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.PubMedCrossRef

Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis. 1996;28(4):596–602.PubMedCrossRef

Portale AA, Booth BE, Halloran BP, Morris RC. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:1580–9.PubMedCrossRef

Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21^waf1 and TGF-Mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. 2001;60(6):2109–17.PubMedCrossRef

10.

Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002;62(4):1196–207.PubMedCrossRef

11.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31(4):607–17.PubMedCrossRef

12.

Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, et al. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: Role of calcium-phosphorus metabolism. J Am Soc Nephrol. 2005;16(9):2796–803.PubMedCrossRef

13.

Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. J Clin Invest. 1995;96:1786–93.PubMedCrossRef

14.

Marks KH, Kilav R, Naveh-Many T, Silver J. Calcium, phosphate, vitamin D, and the parathyroid. Pediatr Nephrol. 1996;10:364–7.PubMed

15.

Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988;67(5):876–81.PubMedCrossRef

16.

Portale AA, Booth BE, Tsai HC, Morris RC. Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int. 1982;21:627–32.PubMedCrossRef

17.

Al-Aly Z, Qazi R, Gonzalez E, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50(1):59–68.PubMedCrossRef

18.

Ghazali A, Fardellone P, Pruna A, Atik A, Achard J-M, Oprisiu R, et al. Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and looser’s zones? J Am Soc Nephrol. 1999;10(6):2169–77.

19.

Elder G, Mackun K. 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res. 2006;21(11):1778–84.PubMedCrossRef

20.

NKF. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis. 2005;46(4 Suppl 1):S1–S121.

21.

NKF. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Supplement 3):S1–S201.

22.

Coen G, Mantella D, Manni M, Balducci A, Nofroni I, Sardella D, et al. 25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005;68(4):1840–8.PubMedCrossRef

23.

Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328–36.PubMedCrossRef

24.

Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D₃ receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436–43.PubMedCrossRef

25.

Schaefer F, Chen Y, Tsao T, Nouri P, Rabkin R. Impaired jak-stat signal transduction contributes to growth hormone resistance in chronic uremia. J Clin Invest. 2001;108(3):467–75.PubMed

26.

Tonshoff B, Powell DR, Zhao D, Durham SK, Coleman ME, Domene HM, et al. Decreased hepatic insulin-like growth factor (IGF)- I and increased igf binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 1997;128(3):938–46.CrossRef

27.

Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. 1994;45:253–8.PubMedCrossRef

28.

Hodson E, Evans R, Dunstan C, Hills E, Shaw P. Quantitative bone histology in children with chronic renal failure. Kidney Int. 1982;21(6):833–9.PubMedCrossRef

29.

Spasovski GB, Bervoets ARJ, Behets GJS, Ivanovski N, Sikole A, Dams G. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18(6):1159–66.PubMedCrossRef

30.

Avila-Diaz M, Matos M, Garcia-Lopez E, Prado M-d-C, Castro-Vazquez F, Ventura MDJ, et al. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis. Perit Dial Int. 2006;26(1):78–84.PubMed

31.

Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int. 1998;53:205–11.PubMedCrossRef

32.

Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58(2):753–61.PubMedCrossRef

33.

Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab. 1992;75:145–50.PubMedCrossRef

34.

Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, et al. Similar predictive value of bone turnover using the first- and second-generation immunometric Pth assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63:1801–8.PubMedCrossRef

35.

Hernandez JD, Wesseling K, Boechat M, Gales B, Salusky IB. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol. 2007;3(4):227–32.PubMedCrossRef

36.

Briese S, Wiesner S, Will J, Lembcke A, Opgen-Rhein B, Nissel R, et al. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease–impact of calcium and vitamin D therapy. Nephrol Dial Transplant. 2006;21(7):1906–14.PubMedCrossRef

37.

Goodman WG, Goldin J, Kuizon B, Yoon C, Gales B, Sider D, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng J Med. 2000;342(20):1478–83.CrossRef

38.

Stenvinkel P, Wang K, Qureshi A, Axelsson J, Pecoits-Filho R, Gao P, et al. Low fetuin-a levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int. 2005;67(6):2383–92.PubMedCrossRef

39.

Davies MR, Lund RJ, Hruska KA. Bmp-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol. 2003;14(6):1559–67.PubMedCrossRef

40.

Moe SM, O, Neill KD, Duan D, Ahmed S, Chen NX, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002;61(2):638–48.PubMedCrossRef

41.

Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF. Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol. 2001;16:318–23.PubMedCrossRef

42.

Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol. 2005;16(5):1494–500.PubMedCrossRef

43.

Lobao R, Carvalho A, Cuppari L, Ventura R, Lazaretti-Castro M, Jorgetti V, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: Bone histomorphometric analysis. Clin Nephrol. 2004;62(6):432–9.PubMed

44.

Andrade M, Carvalhaes L, Carvalho A, Lazaretti-Castro M, Brandao C. Bone mineral density and bone histomorphometry in children on long-term dialysis. Pediatr Nephrol. 2007;22(10):1767–72.PubMedCrossRef

45.

Rix M, Andreassen H, Eskildsen P, Lagdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56(3):1084–93.PubMedCrossRef

46.

Jadoul M, Albert J, Akiba T, Akizawa T, Arab L, Bragg-Gresham J, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006;70:1358–66.PubMedCrossRef

47.

Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115–21.PubMedCrossRef

48.

Lima EM, Goodman WG, Kuizon BD, Gales B, Emerick A, Goldin J, et al. Bone density measurements in pediatric patients with renal osteodystrophy. Pediatr Nephrol. 2003;18:554–9.PubMed

49.

Wehrli F, Leonard M, Saha P, Gomberg B. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imag. 2004;20(1):83–89.CrossRef

50.

Hopper T, Wehrli FW, Saha P, Andre J, Wright A, Sanchez C, et al. Quantitative microcomputed tomography assessment of intratrabecular, intertrabecular, and cortical bone architecture in a rat model of severe renal osteodystrophy. J Comput Assist Tomography 2007;31(2):320–8.CrossRef

51.

Hothi D, Harvey E, Piva E, Keating L, Secker D, Geary D. Calcium and phosphate balance in adolescents on home nocturnal haemodialysis. Pediatr Nephrol. 2006;21(6):835–41.PubMedCrossRef

52.

Goodman WG, Veldhuis JD, Belin TR, Juppner H, Salusky IB. Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism. Kidney Int. 1997;51:1590–5.PubMedCrossRef

53.

Pieper A, Haffner D, Hoppe B, Dittrich K, Offner G, Bonzel K-E, et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with Ckd. Am J Kidney Dis. 2006;47(4):625–35.PubMedCrossRef

54.

Mahdavi H, Kuizon B, Gales B, Wang H, Elashoff R, Salusky IB. Sevelamer hydrochloride: An effective phosphate binder in dialyzed children. Pediatr Nephrol. 2003;18(12):1260–4.PubMedCrossRef

55.

Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol. 2007;18(1):122–30.PubMedCrossRef

56.

Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: Mechanisms and clinical implications. Kidney Int. 2004;66(S90):S39–S45.CrossRef

57.

Bervoets AR, Oste L, Behets GJ, Dams G, Blust R, Marynissen R, et al. Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats. Bone 2006;38(6):803–10.PubMedCrossRef

58.

Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 2005;68(6):2809–13.PubMedCrossRef

59.

Sanchez C, He Y. Bone growth during daily or intermittent calcitriol treatment during renal failure with advanced secondary hyperparathyroidism. Kidney Int. 2007;72(5):582–91.PubMedCrossRef

60.

Scharla S, Strong D, Rosen C, Mohan S, Holick M, Baylink D, et al. 1,25-Dihydroxyvitamin D₃ increases Secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in Vivo. J Clin Endocrinol Metab. 1993;77(5):1190–7.PubMedCrossRef

61.

Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin d receptor activators on vascular calcification in uremic rats. Kidney Int. 2007;72(6):709–15.PubMedCrossRef

62.

Joist H, Ahya S, Giles K, Norwood K, Slatopolsky E, Coyne D. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol. 2006;65(5):335–41.PubMed

63.

Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001;38(5 Suppl 5):S51–S56.PubMedCrossRef

64.

Greenbaum L, Benador N, Goldstein S, Paredes A, Melnick J, Mattingly S, et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis. 2007;49(6):814–23.PubMedCrossRef

65.

Seeherunvong W, Nwobi O, Abitbol C, Chandar J, Strauss J, Zilleruelo G. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol. 2006;21(10):1434–9.PubMedCrossRef

66.

Shah N, Bernardini J, Piraino B. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int. 2005;25(4):362–6.PubMed

67.

Tylavsky F, Ryder K, Li R, Park V, Womack C, Norwood J, et al. Preliminary findings: 25(OH)D levels and PTH are indicators of rapid bone accrual in pubertal children. J Am Coll Nutr. 2007;26(5):462–70.PubMed

68.

Cheng S, Tylavsky F, Kroger H, Karkkainen M, Lyytikainen A, Koistinen A, et al. Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls. Am J Clin Nutr. 2003;78(3):485–92.PubMed

69.

Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25.PubMedCrossRef

70.

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793–800.PubMedCrossRef

71.

Wu S, Palese T, Mishra O, Delivoria-Papadopoulos M, Luca FD. Effects of Ca²⁺-sensing receptor activation in the growth plate. FASEB J. 2004;18(1):143–5.PubMed

72.

Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatr. 2003;111:1030–6.CrossRef

73.

Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: Histomorphometric effects of long-term therapy. J Clin Endocrinol Metab. 2006;91(2):511–6.PubMedCrossRef

Titel: Mineral metabolism and bone abnormalities in children with chronic renal failure
verfasst von: Cheryl P. Sanchez
Publikationsdatum: 01.06.2008
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2008
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-007-9071-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Celiac disease in children: Impact on bone health

Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation

Methods for measurement of pediatric bone

Osteogenesis Imperfecta: Update on presentation and management

Vitamin D deficiency in children and adolescents: Epidemiology, impact and treatment